ClearPoint Neuro Inc vs Marvell Technology Inc — how do they compare? ClearPoint Neuro Inc trades at $15.15 (market cap $454.21M), while Marvell Technology Inc trades at $222.5 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 419.5× ClearPoint Neuro Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | MRVL | |
|---|---|---|
Market Cap | $454.21M | $190.56B |
Sector | Health | Technology |
52-Week High | $29.60 | $316.43 |
52-Week Low | $8.66 | $62.31 |
Enterprise Value | $488.79M | $191.99B |
Dividend Yield | — | 0.11% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.20, up 4.32% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings estimates, with a net income margin of -81.76%. Recent news highlights regulatory progress with partners and expansion into focused ultrasound technology.
The outlook remains speculative with high growth potential in neurotherapy markets, but significant execution and profitability risks persist. Analyst consensus is unanimously bullish, though sustained losses and cash burn require careful monitoring for long-term investors.
Marvell Technology (MRVL) trades at $221.15, up 6.04% today, reflecting strong momentum amid AI-driven optimism. The stock exhibits a bullish technical signal with moving averages supporting the uptrend, while recent earnings beats and a consensus analyst price target of $275.68 highlight fundamental strength. Key developments include partnerships with NVIDIA and Microsoft's Maia 300 AI accelerator, positioning MRVL for growth in data center and networking segments.
Outlook remains positive with AI infrastructure expansion driving revenue projections to $8.7B in 2026, though high valuation ratios (P/E 72.96) and supply chain risks warrant caution. Net income turned profitable in 2026 forecasts, but competitive pressures and market volatility pose challenges. Analyst consensus is strongly bullish with 82% buy ratings, suggesting upside potential if execution aligns with growth expectations.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →